CD274 and neoplasm: Using fresh and archival tumor samples from dose-escalation and dose-expansion phases of the CheckMate 040 trial for IHC and RNA sequencing, PD-L1-positive patients treated with nivolumab monotherapy had an increased median OS of 28.1 months versus 16.6 months among patients who were PD-L1-negative (p = 0.03) [137].